BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, July 13, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Sparx receives IND clearance for bispecific antibody SPX-303
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Sparx receives IND clearance for bispecific antibody SPX-303
Oct. 31, 2023
Sparx Biopharmaceutical Corp. has received FDA approval of its IND application for SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody drug candidate.
BioWorld Science
Cancer
Bispecific antibody
Immuno-oncology